At present, there is no generic drug of Eplerenone on the market in China. The original product name of the drug is Inspra, developed by Pfizer. It is a selective aldosterone receptor antagonist mainly used for the treatment of hypertension and heart failure after myocardial infarction.

1. Current situation of generic drugs

(1) Domestic situation: As of September 2025, no generic drugs of eplerenone have been approved for market in China, and patients need to use the original drug.

(2) International situation: Some countries have already obtained approval for generic drugs, but they have not been approved by the Chinese drug regulatory authorities to enter the domestic market.

Basic information of 2 original drugs

(1) Product name: Inspra, commonly known as Eplerenone.

(2) R&D company: Developed and produced by Pfizer Inc. in the United States.

(3) Listing status: It has been officially listed in China and can be purchased through legitimate channels.

3 Drug Characteristics

(1) Dosage form specification: 25mg/tablet, yellow diamond shaped film coated tablets, packaged in boxes of 30 tablets.

(2) Mechanism of action: Selective blockade of mineralocorticoid receptors (MR), reducing sodium reabsorption and potassium excretion.

4 Indications

(1) Hypertension treatment: can significantly reduce the incidence of cardiovascular events, especially for stroke and myocardial infarction.

(2) Heart failure treatment: Improve the survival rate of heart failure patients with reduced ejection fraction after acute myocardial infarction.